Contrasting Axonics (NASDAQ:AXNX) & Orthofix Medical (NASDAQ:OFIX)

Axonics (NASDAQ:AXNX) and Orthofix Medical (NASDAQ:OFIX) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, dividends, earnings, valuation, institutional ownership, profitability and analyst recommendations.

Profitability

This table compares Axonics and Orthofix Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Axonics	-4.12%	-2.58%	-2.32%
Orthofix Medical	-16.64%	-14.24%	-9.49%

Earnings and Valuation

This table compares Axonics and Orthofix Medical’s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Axonics	$366.38 million	9.53	-$6.09 million	($0.32)	-213.88
Orthofix Medical	$760.05 million	0.80	-$151.40 million	($3.38)	-4.79

Axonics has higher earnings, but lower revenue than Orthofix Medical. Axonics is trading at a lower price-to-earnings ratio than Orthofix Medical, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Axonics and Orthofix Medical, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Axonics	0	8	2	0	2.20
Orthofix Medical	0	3	2	0	2.40

Axonics presently has a consensus price target of $69.57, indicating a potential upside of 1.65%. Orthofix Medical has a consensus price target of $18.00, indicating a potential upside of 11.11%. Given Orthofix Medical’s stronger consensus rating and higher probable upside, analysts plainly believe Orthofix Medical is more favorable than Axonics.

Risk & Volatility

Axonics has a beta of 0.83, suggesting that its stock price is 17% less volatile than the S&P 500. Comparatively, Orthofix Medical has a beta of 1.05, suggesting that its stock price is 5% more volatile than the S&P 500.

Insider & Institutional Ownership

99.5% of Axonics shares are owned by institutional investors. Comparatively, 89.8% of Orthofix Medical shares are owned by institutional investors. 1.9% of Axonics shares are owned by company insiders. Comparatively, 4.7% of Orthofix Medical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Axonics beats Orthofix Medical on 7 of the 13 factors compared between the two stocks.

About Axonics

Axonics, Inc., a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct sales force and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California.

About Orthofix Medical

Orthofix Medical Inc. operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions. This segment also designs, develops, and markets a portfolio of navigation technologies, including tracked surgical tools, intelligent software, and imaging equipment based on machine-vision and optical innovations. The Global Orthopedics segment offers products and solutions that allow physicians to treat various orthopedic conditions related to limb reconstruction and deformity correction unrelated to the spine. This segment designs, develops, and markets external and internal fixation orthopedic products that are coupled with enabling digital technologies to serve the complete patient treatment pathway. It sells its products through distributors and sales representatives to hospitals, healthcare organizations, and healthcare providers. The company was formerly known as Orthofix International N.V. and changed its name to Orthofix Medical Inc. in 2018. Orthofix Medical Inc. was founded in 1980 and is headquartered in Lewisville, Texas.